Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study

Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study

Background Vaccination remains the cornerstone of defense against COVID-19 globally. This study aims to assess the safety and immunogenicity profile of innovative vaccines LYB001.Research design and methods This was a randomized, double-blind, parallel-controlled trial, in 100 healthy Chinese adults...

Full description

Saved in:
Bibliographic Details
Main Authors: Rong Tang, Ying Zeng, Yu Zhou, Qi Liang, Wei Kang, Zhonghua Yang, Xiaoxiang Zheng, Xia Zang, Hongxing Pan, Jing Jin, Fengcai Zhu
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Expert Review of Vaccines
Subjects:
COVID-19 vaccine
recombinant protein
virus-like particle (VLP)
safety
tolerance
immunogenicity
Online Access:https://www.tandfonline.com/doi/10.1080/14760584.2024.2337051
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items